Inovio Pharmaceuticals Inc

Find Ratings Reports
INO : NASDAQ : Health Care
$5.51 -0.43 | -7.24%
Today's Range: 5.5 - 6.01
Avg. Daily Volume: 2003300.0
07/27/17 - 4:00 PM ET

Financial Analysis


INOVIO PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. INOVIO PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.52 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 38.08% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)10.388.11
EBITDA ($mil)-21.01-14.85
EBIT ($mil)-21.93-15.45
Net Income ($mil)-23.09-8.04


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)89.66146.79
Total Assets ($mil)153.31211.29
Total Debt ($mil)0.00.0
Equity ($mil)105.85170.97


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin-202.44-183.14
EBITDA Margin-202.43-183.14
Operating Margin-211.39-190.52
Sales Turnover0.250.21
Return on Assets-57.9-12.61
Return on Equity-83.87-15.58
Debt Q1 FY17 Q1 FY16
Current Ratio2.674.81
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)74.6372.27
Div / share0.00.0
EPS-0.31-0.11
Book value / share1.422.37
Institutional Own % n/a n/a
Avg Daily Volume1847669.0749592.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 4.24 indicates a premium versus the S&P 500 average of 3.07 and a significant discount versus the industry average of 11.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, INOVIO PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
INO NM Peers 44.01   INO NM Peers 43.69

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

INO's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

INO's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
INO NM Peers 27.93   INO NA Peers 0.55

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

INO's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
INO 4.24 Peers 11.44   INO -215.78 Peers -7.96

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

INO is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, INO is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
INO 11.92 Peers 190.63   INO -13.52 Peers 434.91

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

INO is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

INO significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades